Inavolisib + Fulvestrant for Breast Cancer

(optINAVO Trial)

This trial tests a new combination of treatments: inavolisib (a potential new drug) and fulvestrant (a hormone therapy) for individuals with a specific type of breast cancer. The focus is on breast cancer with a PIK3CA mutation, hormone receptor-positive (HR-positive), and lacking excessive HER2 protein. Participants should have experienced cancer progression despite previous treatments with a CDK inhibitor and hormone therapy. For those with this specific type of breast cancer, if hormone therapy is recommended over chemotherapy, this trial might be suitable. As a Phase 2 trial, the research measures the treatment's effectiveness in an initial, smaller group of participants.

The trial information does not specify if you need to stop taking your current medications. However, if you have Type 2 diabetes requiring ongoing treatment or have been treated with certain cancer drugs before, you may not be eligible.

Research has shown that the combination of inavolisib and fulvestrant is generally safe. One study found that patients usually tolerated inavolisib well, even when taken for a year or more. However, some patients experienced mouth inflammation, with 51% reporting this side effect, and in 6% of cases, it was more severe.

Researchers are excited about Inavolisib combined with Fulvestrant for breast cancer because Inavolisib targets the PI3K pathway, which plays a crucial role in cancer cell growth and survival. Unlike standard treatments like aromatase inhibitors or chemotherapy, which have broader mechanisms, Inavolisib offers a more targeted approach, potentially improving effectiveness and reducing side effects. Additionally, combining Inavolisib with Fulvestrant, a hormone therapy that blocks estrogen receptors, could provide a dual-action strategy to combat hormone receptor-positive breast cancer more effectively. This innovative combination might offer new hope to patients who have not responded well to existing therapies.

Research has shown that combining inavolisib with fulvestrant may help treat certain types of breast cancer. This trial will evaluate two different doses of inavolisib combined with fulvestrant. Studies have found that adding inavolisib to treatments like fulvestrant significantly improved survival rates in patients with a specific type of advanced breast cancer. Specifically, patients lived a median of 34 months compared to 27 months for those who did not receive inavolisib. Additionally, this combination helped patients live longer without their cancer worsening. These findings suggest that inavolisib, when used with fulvestrant, could be an effective treatment option for this type of breast cancer.⁶⁷⁸⁹¹⁰